prepar
seri
peptidelik
macrocycl
contain
acid
scaffold
use
known
coupl
reagent
protect
group
strategi
yield
purifi
macrocycl
poor
averag
yet
seemingli
independ
amino
acid
substitut
stereochemistri
macrocycl
retain
level
conform
variabl
observ
molecular
model
xray
crystallographi
macrocycl
repres
new
class
structur
develop
futur
applic
highthroughput
screen
varieti
biolog
target
natur
product
contain
wide
varieti
conformationallyconstrain
macrocycl
peptidebas
ring
present
backbon
side
chain
pharmacophor
group
interact
biolog
target
biologicallyact
compound
gener
use
plant
anim
chemic
warfar
order
gain
advantag
competitor
assault
peptid
base
macrocycl
marin
sourc
continu
investig
biolog
activ
similar
compound
plant
medicin
chemist
long
use
macrocycl
tool
drug
discoveri
classic
illustr
techniqu
discoveri
potent
cyclic
peptid
somatostatin
mimic
three
decad
ago
use
cycliz
sinc
develop
gener
paradigm
peptidomimet
drug
design
wide
use
discoveri
biologicallyact
compound
studi
cell
inde
natur
product
synthet
macrocycl
peptid
known
anticanc
use
potenti
therebi
illustr
function
similar
oxazol
thiazol
well
oxazolin
thiazolin
ring
commonli
found
natur
product
macrocycl
peptid
sever
research
group
report
synthesi
macrocycl
peptid
contain
heterocycl
amino
acid
heterocycl
amino
acid
incorpor
cyclic
peptid
includ
pyridin
addit
potenc
select
gain
macrocycl
peptid
cyclic
peptid
also
resist
proteolyt
degrad
metabol
plu
cell
permeabl
correspond
linear
peptid
import
consider
compound
valuabl
chemic
tool
studi
cell
report
synthesi
character
peptidelik
macrocycl
librari
contain
acid
therebi
yield
uniqu
compound
class
inspir
macrocycl
natur
product
known
paradigm
drug
discoveri
final
compound
macrocycl
variat
stereochemistri
amino
acid
side
chain
side
chain
variat
limit
comparison
possibl
nonetheless
illustr
abil
form
macrocycl
regardless
stereochemistri
larger
side
chain
inde
macrocycl
underrepres
screen
librari
due
part
synthet
challeng
work
import
first
step
develop
acidbas
macrocycl
screen
effort
valu
acid
scaffold
drug
discoveri
previous
report
librari
screen
effort
built
around
scaffold
librari
member
obey
lipinski
ruleoff
druglik
compound
also
limit
conform
flexibl
favor
pharmacokinet
properti
regardless
toollik
compound
outsid
molecular
weight
hydrogen
bond
donor
acceptor
log
p
valu
still
valuabl
use
earli
screen
chemic
genom
research
import
note
macrocycl
repres
new
compound
class
differ
small
compound
librari
previous
report
use
acid
scaffold
featur
mimic
known
bioactiv
natur
product
anticip
compound
would
reason
pharmacokinet
properti
thu
reason
macrocycl
valuabl
screen
effort
varieti
bioassay
result
report
time
build
block
synthesi
macrocycl
shown
chart
synthesi
macrocycl
begin
commerci
avail
n
ndialkylalkanediamin
shown
scheme
monoprotect
benzyloxycarbonyl
chlorid
use
excess
diamin
yield
follow
workup
purif
similarli
report
howev
method
work
poorli
result
signific
amount
diprotect
diamin
altern
synthesi
therefor
use
employ
nboc
protect
first
follow
benzyloxycarbonyl
chlorid
protect
give
orthogon
protect
diamin
subsequ
remov
nboc
protect
group
cf
co
h
ch
cl
yield
intermedi
coupl
bocamino
acid
build
block
edc
dmap
ch
cl
provid
chemset
hydrogenolysi
chemset
meoh
yield
chemset
follow
workup
pyrazin
build
block
prepar
previous
describ
react
chemset
ch
cl
yield
acycl
chemset
follow
purif
column
chromatographi
stoichiometri
reaction
chemset
chemset
respect
yield
equival
chemset
tertbutyl
ester
nboc
protect
group
remov
use
cf
co
h
ch
cl
trifluoroacet
exchang
chlorid
ad
dilut
hcl
freez
solut
lyophil
give
chemset
macrocycl
ring
closur
chemset
affect
dissolv
chemset
ch
cl
ad
edc
dmap
final
macrocycl
also
purifi
column
chromatographi
character
lcm
hnmr
spectroscopi
scheme
synthet
strategi
macrocycl
synthesi
extens
effort
made
optim
synthesi
macrocycl
yield
purifi
macrocycl
poor
across
seri
averag
yield
best
yield
singl
reaction
tri
form
macrocycl
hbtu
et
n
dmf
attempt
product
observ
lcm
analysi
inde
final
product
identifi
nine
attempt
macrocycl
reaction
start
materi
isol
addit
four
macrocycl
leav
plan
macrocycl
synthes
studi
yield
chromatographicallypur
macrocycl
given
tabl
importantli
observ
clear
trend
relat
stereochemistri
size
side
chain
prevent
format
macrocycl
reason
would
possibl
expand
librari
futur
includ
greater
divers
area
result
nonetheless
import
critic
first
step
goal
target
screen
librari
close
relat
compound
especi
given
gener
challeng
synthesi
macrocycl
final
macrocycl
contain
three
hydrogen
bond
donor
five
hydrogen
bond
acceptor
therebi
conform
principl
fewer
five
hydrogen
bond
donor
hydrogen
bond
acceptor
outlin
lipinski
ruleoff
druglik
compound
final
macrocycl
molecular
weight
clogp
valu
provid
tabl
molecular
weight
less
gmol
clogp
valu
rang
clearli
desir
limit
xray
crystallographi
done
order
gain
insight
conform
macrocycl
ring
system
select
crystal
data
provid
tabl
interestingli
four
differ
conform
observ
asymmetr
unit
label
conform
conform
b
conform
c
conform
crystal
structur
also
four
conform
label
conform
ad
xray
crystal
structur
two
conform
label
conform
b
xray
crystal
structur
label
diagram
macrocycl
averag
torsion
angl
deviat
four
conform
ad
averag
torsion
angl
deviat
two
conform
b
illustr
conform
shown
ballandstick
represent
well
compar
torsion
angl
observ
energyminim
structur
given
tabl
four
conform
observ
xray
crystal
structur
data
present
averag
observ
deviat
torsion
angl
two
conform
observ
xray
crystal
structur
data
present
averag
observ
deviat
torsion
angl
embolden
torsion
angl
outsid
rang
observ
conform
ad
crystal
structur
ballandstick
illustr
conform
xray
crystal
structur
torsion
angl
glycin
residu
conform
ad
princip
site
observ
variabl
conform
found
crystal
structur
evidenc
valu
deviat
angl
compar
other
macrocycl
particularli
surpris
glycin
quit
flexibl
rel
natur
amino
acid
yet
surpris
find
consider
variabl
torsion
angl
leucin
along
strike
similar
torsion
angl
n
ndiethylethylenediamin
linker
would
expect
diamin
torsion
angl
observ
site
differ
amino
acid
residu
hindsight
reason
relat
strong
intramolecular
hydrogen
bond
seen
conform
asymmetr
unit
across
crystal
structur
although
crystal
pack
influenc
rule
observ
nh
distanc
hydrogen
bond
across
conform
ad
xray
crystal
structur
well
conform
b
provid
tabl
compar
valu
observ
energyminim
structur
also
given
tabl
torsion
angl
leucin
dalanin
also
princip
site
variabl
conform
ad
observ
xray
crystal
structur
evidenc
larger
deviat
angl
compar
torsion
angl
smaller
deviat
respect
torsion
angl
glycin
dalanin
residu
observ
two
conform
b
although
greater
deviat
still
signific
compar
torsion
angl
macrocycl
indic
intramolecular
hydrogen
bond
observ
crystal
structur
previous
note
across
wide
varieti
acid
deriv
amino
acid
chemset
provid
donor
nh
intramolecular
hydrogen
bond
acceptor
come
scaffold
macrocycl
form
intermolecular
dimer
solidst
imidazol
nh
amid
carbonyl
scaffold
form
nh
hydrogen
bond
respect
amino
acid
chemset
synthet
scheme
interact
observ
asymmetr
unit
xray
crystal
structur
illustr
figur
structur
b
c
molecular
model
done
order
compar
torsion
angl
observ
energyminim
structur
averag
torsion
angl
four
conform
ad
xray
crystal
structur
tabl
interestingli
major
torsion
angl
energyminim
model
deviat
observ
rang
seen
across
conform
ad
two
torsion
angl
connect
intramolecular
hydrogen
bond
acceptor
imidazol
ring
fall
observ
rang
yet
paramet
intramolecular
hydrogen
bond
energyminim
structur
compar
rang
four
conform
ad
crystal
structur
tabl
sourc
differ
clear
time
variabl
torsion
angl
consid
advantag
futur
screen
applic
macrocycl
librari
think
macrocycl
provid
overal
preorgan
scaffold
retain
enough
torsion
angl
variabl
amino
acid
residu
help
optim
bind
interact
side
chain
pharmacophor
target
apparatu
ovendri
cool
desicc
reagent
purchas
commerci
supplier
use
without
purif
except
reagent
grade
ch
cl
distil
cah
use
thin
layer
chromatographi
tlc
perform
glassback
silica
gel
plate
visual
use
uv
column
chromatographi
perform
silica
gel
merck
grade
mesh
column
prepar
plastic
ml
syring
bodi
fill
approxim
capac
silica
gel
character
puriti
ident
librari
member
intermedi
carri
liquid
chromatographymass
spectrometri
lcm
use
varian
lc
ion
trap
mass
spectromet
solut
compound
prepar
approxim
concentr
mgml
first
ad
volum
ch
cl
dissolv
sampl
dilut
final
volum
hplc
grade
methanol
five
microlit
sampl
inject
onto
polari
mm
mm
hplc
column
elut
gradient
ch
cnh
contain
ch
co
h
mlmin
flow
rate
compound
detect
nm
gradient
follow
min
ch
cnh
min
ch
cnh
min
ch
cnh
min
ch
cnh
min
ch
cnh
min
ch
cnh
mass
spectrum
record
entir
elut
time
use
esi
detect
mz
follow
paramet
capillari
voltag
rf
load
dri
ga
spray
chamber
nebul
ga
psi
dri
ga
psi
damp
ga
mlmin
hnmr
cnmr
spectra
record
intermedi
mhz
mhz
respect
cdcl
chcl
intern
refer
h
cdcl
intern
refer
c
dmsod
dmso
intern
refer
h
dmsod
intern
refer
sampl
xray
diffract
obtain
slow
evapor
wet
methanol
solut
data
use
radiat
collect
bruker
apex
ii
ccd
integr
saint
xprep
order
provid
observ
reflect
fo
fo
crystal
stabil
monitor
measur
three
standard
reflect
everi
reflect
signific
decay
observ
intens
scan
techniqu
use
peak
collect
lorenz
polar
correct
appli
hydrogen
atom
posit
locat
differ
fourier
map
ride
model
fix
thermal
paramet
uij
eq
atom
bond
use
subsequ
refin
packag
use
data
reduct
structur
solut
refin
ccdc
contain
supplementari
crystallograph
data
paper
data
obtain
free
charg
via
wwwccdccamacukcontsretrievinghtml
ccdc
union
road
cambridg
uk
fax
email
deposit
ccdccamacuk
use
calcul
lowenergi
conform
conform
librari
gener
lowest
energi
conform
minim
semiempir
method
lowest
energi
conform
molecular
model
compar
four
conform
ad
observ
solidst
xray
crystallographi
procedur
provid
protect
n
ndialkylalkanediamin
along
gener
method
remain
intermedi
final
macrocycl
specif
exampl
intermedi
one
macrocycl
also
provid
remain
synthet
detail
analyt
data
provid
esi
synthesi
done
previous
describ
briefli
dri
roundbottom
flask
argon
ad
dri
ch
cl
stir
solvent
ad
order
pyrazin
diacid
chlorid
equiv
amino
acid
ester
hydrochlorid
salt
equiv
n
ndiethylanilin
equiv
result
solut
held
min
stir
room
temperatur
reaction
wash
water
organ
fraction
dri
mgso
filter
concentr
residu
suspend
boil
etoac
stir
min
cool
solid
product
collect
vacuum
filtrat
wash
etoac
final
product
character
hnmr
spectroscopi
tabl
macrocycl
peptid
use
tool
drug
discoveri
owe
part
conform
preorgan
pharmacophor
reduc
proteolyt
degrad
metabol
well
increas
bioavail
compar
acycl
peptid
acid
use
scaffold
drug
discoveri
readili
diversifi
amin
yield
illustr
abil
deriv
modifi
peptidelik
macrocycl
ring
final
product
natur
productlik
synthesi
accept
modif
stereochemistri
amino
acid
side
chain
yield
chromatograph
pure
final
product
poor
time
effort
optim
macrocycl
extend
type
substitu
present
macrocycl
ring
undertaken
product
may
also
valuabl
screen
collect
look
hit
wide
varieti
drug
target
effort
report
due
time
supplementari
materi
access
http
